← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Ophirex, Inc.
Corte Madera, CA
$2,890,656
Total funding
1
Grants
Funding over time
peak $1.1M · FY2023–25$2M$1.5M$1M$500K$0
'23
'24
'25
Funding mix
By agency
FDA$2,890,656 · 1
By mechanism
R01$2,890,656 · 1
Investigators at Ophirex, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Development of Intravenous Varespladib, a Phospholipase A2 Inhibitor, for the Treatment of Snakebite Envenoming$1,109,888
R01 · FY2025 · FD
Development of Intravenous Varespladib, a Phospholipase A2 Inhibitor, for the Treatment of Snakebite Envenoming$894,459
R01 · FY2023 · FD
Development of Intravenous Varespladib, a Phospholipase A2 Inhibitor, for the Treatment of Snakebite Envenoming$886,309
R01 · FY2024 · FD